Use of ciprofloxacin in patients undergoing transurethral prostatic surgery

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Standard

Use of ciprofloxacin in patients undergoing transurethral prostatic surgery. / Hellsten, Sverker; Forsgren, Arne; Björk, Thomas; Grabe, Magnus.

I: Scandinavian Journal of Infectious Diseases. Supplementum, Vol. 60, 1989, s. 104-107.

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Harvard

APA

CBE

MLA

Vancouver

Author

RIS

TY - JOUR

T1 - Use of ciprofloxacin in patients undergoing transurethral prostatic surgery

AU - Hellsten, Sverker

AU - Forsgren, Arne

AU - Björk, Thomas

AU - Grabe, Magnus

N1 - The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Pediatrics/Urology/Gynecology/Endocrinology (013240400), Division of Urological Cancers (013243420), Clinical Microbiology, Malmö (013011000), Urology (013243400)

PY - 1989

Y1 - 1989

N2 - The efficacy of a short (Group I) and a prolonged (Group II) course with ciprofloxacin was assessed in patients undergoing transurethral prostatic resection and compared with that of controls without antibiotic (Group III). Both regimens significantly reduced the frequency of post-operative bacteriuria (p less than 0.01) and of severe infectious complications (p = 0.004) compared to the controls. Both regimens were equally effective in preventing peri-operative and post-operative acquisition of bacteriuria in patients without bacteriuria at surgery. In patients with bacteriuria before surgery, bacteriuria was found post-operatively in 35% in Group I and in 9% in Group II (p = 0.012), but in 82% of the patients in Group III. Ciprofloxacin inhibited all but 7 of 176 bacterial strains at an MIC of less than or equal to 1 microgram/ml. Given orally, ciprofloxacin is a valuable alternative antimicrobial for use in conjunction with transurethral prostatic resection. A short course is sufficient for prophylaxis, and adequate therapy is achieved with a prolonged regimen.

AB - The efficacy of a short (Group I) and a prolonged (Group II) course with ciprofloxacin was assessed in patients undergoing transurethral prostatic resection and compared with that of controls without antibiotic (Group III). Both regimens significantly reduced the frequency of post-operative bacteriuria (p less than 0.01) and of severe infectious complications (p = 0.004) compared to the controls. Both regimens were equally effective in preventing peri-operative and post-operative acquisition of bacteriuria in patients without bacteriuria at surgery. In patients with bacteriuria before surgery, bacteriuria was found post-operatively in 35% in Group I and in 9% in Group II (p = 0.012), but in 82% of the patients in Group III. Ciprofloxacin inhibited all but 7 of 176 bacterial strains at an MIC of less than or equal to 1 microgram/ml. Given orally, ciprofloxacin is a valuable alternative antimicrobial for use in conjunction with transurethral prostatic resection. A short course is sufficient for prophylaxis, and adequate therapy is achieved with a prolonged regimen.

M3 - Article

VL - 60

SP - 104

EP - 107

JO - Scandinavian Journal of Infectious Diseases, Supplement

JF - Scandinavian Journal of Infectious Diseases, Supplement

SN - 0300-8878

ER -